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INTRODUCTION: 
              Globally among various diseases, cancer has become a major 
threat to human beings. It has now become a disease which has perplexed 
many, doctors and patients alike is now one  of the leading causes of 
death worldwide .As per Indian population census data, cancer related 
mortality rates are high and alarming. In India, cancer has become the 
most common disease, ranking second. It has become responsible for 
high mortality rates, with about 0.3 million deaths per year. This is 
mainly because of availability of resources is poor in a country ours. The 
resources are limited not only for prevention, screening,  but also for 
diagnosis and treatment. 
 
            The cancer burden continues to increase globally, largely because 
of the aging of the population and also due to growth of the young 
population alongside with  increase in  adoption of cancer-causing 
behaviours, especially in economically developing countries.  In our 
country the increase in cancer burden is mainly attributed to urbanisation, 
industrialisation, changes in life style , increase in  population and 
increase in life span. The life expectancy has risen from 45 years in 
1970’s to 62 years in 1990’s and 71 years is expected by 2021. Many 
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cancers are found to have some relation with the diet habits, one  among 
them are cancers of gastrointestinal tract. 
 
 
IMPACT OF CANCER IN INDIA: 
Impact of cancer is much greater in India, than the mere number of 
cases of cancer. The very beginning of diagnosis of cancer causes 
immense emotional trauma to the patients and to their families, and its 
treatment a major economic burden. The diagnosis of cancer itself is  
perceived by most of them as a grave event, a curse with more than one-
third of them suffering from some form of mood disorders (anxiety and 
depression). The family members also feel equally distressed. It could 
affect both family’s daily functioning and economic situation. The 
economic blow often includes both loss of income and increase of 
expenses because of treatment and health care.  In a country like India 
this disease is associated with a lot of fear & despair. 
 
CANCER MANAGEMENT A CHALLENGE IN INDIA: 
According to a study conducted by Boston Consulting Group , 70% 
cancer cases in India are diagnosed at  advanced stages and,  most of the 
patients do not have access to  tertiary care centres. There are  not many  
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cancer centers in India to meet the demand of treatment burden. More 
radiotherapy centers with adequate number of machines are required to 
cover cancer population adequately. Moreover, not all centers are well 
equipped with modern facilities.  The  current Doctor patient ratio is only 
1 in 2000 and aim is to achieve, atleast 1 in 1000 by  the year 2021.There 
is also disproportionate skillful manpower and technology with  very few 
cancer specialists, trained staff available. And if present, these specialized 
cancer centers are available only in very few cities across India. For most 
patients in India,  treatment cost is so heavy and out of reach. Neither  
people do not have insurance cover.Thus delivery of equitable, quality 
and affordable cancer care in India is a big challenge. 
 
INCIDENCE OF COLORECTAL CANCERS:  
The specialised cancer wing of the world health organisation, 
International Agency for Research on Cancer (IARC), released the latest 
data on cancer incidence, mortality, and prevalence worldwide in 
December  2013.(1) Their online database GLOBOCAN 2012, revealed the 
most recent estimates of incidence and prevalence rates of different 
cancers. Colorectal cancer has become the third most common cancer 
worldwide, with nearly 1.4 million new cases diagnosed in the year  
2012. Of  these ,majority of    patients were men constituting about 7.4 
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million cases and women 6.7 million. This number is expected to rise to 
2.4 million cases worldwide by 2035.It is predicted that worldwide, by 
the year 2035, the number of colorectal cases will increase  to 1.36 
million for men and for women 1.08 million. 
(2)
 
 Amomg  both sexes 
 Lung cancer was the most common cancer worldwide constituting 
13% of new cases diagnosed in 2012. 
 Breast cancer (women only) was the second most common cancer 
with nearly 1.7 million new cases in 2012. 
 Colorectal cancer was the third most common cancer with 
nearly 1.4 million new cases in 2012. 
 
 
GEOGRAPHIC VARIATIONS: 
The  incidence of colorectal cancers is not uniform throughout the 
world. There is a large geographic variation in the global 
distribution.colorectal cancer. Colorectal cancer is mainly a disease 
of western developed countries with a with ten fold variation 
between countries with the highest rates than those with the lowest 
rates. It ranges from more than 40 per 100,000 people in the United 
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States, Australia, New Zealand, and Western Europe to less than 5 
per 100,000 in Africa and some parts of Asia.(3) 
 
 
MORTALITY RATES AND TRENDS: 
Worldwide mortality due to colorectal cancer is approximately half 
of   its incidence. Nearly about 530,000 deaths were recorded in the year   
2012 , and it contributed  to 8% of all cancer  related deaths. In the United 
States,both in men and women , it has become the second leading cause 
of death among other cancers. The incidence rates are appropriate 
indicator of trends in disease occurrence. Colorectal cancer incidence is 
unaffected by changes in treatment and survival, although it has been 
shown to be influenced by improved diagnostic techniques and screening 
programs.(4) 
 
CANCER SURVIVAL AND PROGNOSIS: 
Survival is highly dependent upon stage of disease at the time of 
diagnosis, and 5-year survival rate ranges from  90% for cancers detected 
at the localized stage to 70% for regional and to 10% for patients 
diagnosed with distant metastasis. With recent  improvements in 
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treatment strategies survival for all stages of colorectal cancer at has 
increased significantly. The better improvement in 5-year survival is seen 
in countries with high life-expectancy and good access to modern 
specialized treatment centers. Even then ,large disparities exist in 
colorectal cancer survival worldwide and even within same regions. (4) 
 
RISK FACTORS: 
  There are many number of risk factors associated with increased 
incidence of colorectal cancer. Non modifiable risk factors are the ones 
that one cannot control, it includes age and inhereted factors. In addition 
to this, other factors in environment and lifestyle habits play a significant 
role in the development of colorectal cancer. 
 
1. Age: 
The likelihood of developing colorectal cancer increases as age 
increases above  40 .It sharply  rises after 50 years of age. More than 90% 
of colorectal cancer cases occur in people aged 50 years or older. 
However, it seems to be  increasing among younger population too, 
mainly because of western life style and dietary habits .  
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2. Personal History of Adenomatous Polyps: 
Almost 95% of colorectal cancers due to sporadic causes develop 
from  adenomatous polyps. Neoplastic polyps namely tubular and villous  
Adenomas serve as the  are precursor lesions for developing cancer .   An 
person with a history of adenomatous polyps has an higher risk of 
developing colorectal cancer, than individuals with no such history of 
adenomas. A long latency period of about  5 to 10 years is  required for 
transformation from ademomas to invasive lesions. Screening , early 
detection of these adenomatous polyps  with subsequent removal before 
malignant transformation may reduce the risk of colorectal 
cancer. However, there always remains an increased risk  of further 
development of metachronous cancers anywhere in the colon or rectum.  
3. Personal History of Inflammatory Bowel Disease: 
Inflammatory bowel disease (IBD) includes two  main diseases, 
Crohn disease and ulcerative colitis. Crohn disease can involve any part 
of the gastro intestinal tract and it causes inflammation of the full 
thickness of the bowel wall. . Ulcerative colitis  usually involves only 
colon and rectum. And it causes only mucosal inflammation. Both these 
inflammatory diseases increase the  overall risk of developing colorectal 
cancer. The relative risk of patients with inflammatory bowel disease to 
develop colorectal cancers is estimated between 4- to 20-fold. Therefore, 
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individuals with inflammatory bowel diseases regardless of age are 
encouraged to  undergo screening  for colorectal cancer  more frequently  
than the general population.  
 
4. Family History of Colorectal Cancer or Adenomatous Polyps : 
 In about 20% of people who develop colorectal cancer have 
positive family history . It is higher in people with affected first degree 
relative younger than 60 years of age , or a history of colorectal cancer or 
adenomatous polyps in two or more first-degree relatives at any age. The 
increased risk is attributed  to inherited genes, shared environmental 
factors, or combination of these factors. 
 
 
5. Inherited Genetic Risk: 
Nearly 5 to 10% of colorectal cancers are have recognisable 
hereditary factors. The most common among the inherited conditions 
include  familial adenomatous polyposis (FAP)  and ,Lynch syndrome 
also known as  hereditary nonpolyposis colorectal cancer (HNPCC). 
Genes causing these forms of inherited colorectal cancer have been 
identified. HNPCC is associated with mutations in genes 
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the MLH1 and MSH2 , which are  involved in the repair pathway 
DNAs. FAP is caused by mutations in APC genes ,which is a tumor 
suppressor gene . Lynch syndrome  accounts for only 6 %  of colorectal 
cancers, and individuals have a lifetime risk of developing  cancer is as 
high as 70 to 80%.The average age at diagnosis  is also younger , around 
40 years.   Patients with genetic mutations in genes involved in  DNA 
mismatch repair   , are also at a higher risk of developing  many other 
cancers, namely cancer of the genitourinary tract, stomach, small bowel 
and  pancreas.  FAP accounts for only very few cases less than 
1%. Unlike people  with HNPCC, who develop only a few adenomas,  
individuals  with FAP characteristically develop hundreds of polyps, at a 
relatively younger age, and one or more of these adenomatous polyps  
typically undergoes malignant transformation  at a very early . All 
individuals  with FAP, will  developed cancer before  the age of 40 if the 
colon is not removed prophylactically. APC-gene is inherited in an 
autosomal dominant fashion. Nearly 80% of people with APC-associated 
polyposis have atleast  one affected parent. Prenatal testing and 
preimplantation genetic testing should be done , if the mutation is 
identified in  any one of the parent. 
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6. Environmental Risk Factors : 
Colorectal cancer  develops  due to various  environmental factors, 
which includes cultural, social, and lifestyle modification . Colorectal 
cancer has many modifiable causes identified, and a significant 
proportion of cases may  be theoretically preventable. Some of the 
evidence of environmental risk factors as causes comes from studies of 
migrants and their offspring. Between migrants from low-risk to high-risk 
countries, incidence rates tends to increase toward those of the 
populationbelonging to  the host country.  The incidence of colorectal 
cancer in the offspring of migrants from Japan to  United States, equal to 
or it  may surpasses that in naïve American population. This is three or  
four times higher than among the Japanese in Japan. Not only  migration, 
there are other geographic factors influencing incidence  rates too. One 
among  them is living in urban residence. The incident rates are 
constantly found to be  higher among urban residents. This excess 
incidence in urban areas is more apparently seen in males than females , 
and more so for colon cancer than rectal cancer.  
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7. Dietary habits: 
Diet strongly influences the risk of colorectal cancer .  Several 
studies have shown that changes in food habits may reduce to 70% of this 
cancer incidence . Diets rich in fat, especially fats of animal origin has 
shown to be a  major risk. The association of animal fat, as a possible 
etiologic factor, is linked to the concept of the Westernization of  diet 
habits, which  favors  the growth of gut bacterial flora. These are capable 
of degrading  the bile salts to potentially carcinogenic N-nitroso 
compounds. Consumption of high meat has also shown to an risk factor 
in the development of colorectal cancer. This positive association  of 
cancer with meat consumption is more so for colon cancer than rectal 
cancer. It  is mainly because of presence ofm heme iron in red meat. In 
addition to this ,some meats products  are cooked at very high 
temperatures, resulting in the production of heterocyclic amines and 
polycyclic aromatic hydrocarbons. Both of these compounds  are believed 
to be carcinogenic .  
Some studies have shown that individuals whose food habits includes 
less fruits and vegetables , have a relatively  higher risk of cancer. Differences 
in dietary fiber consumption might be responsible for the geographic variation 
in the  incidence rates. The basic  mechanism is that increased  
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intake of dietary fiber may cause  dilution of  fecal content thereby 
increasing the  fecal bulk, and reducing  the  bowel transit time.  
 
 
8. Physical Activity and Obesity : 
Several habits related to lifestyle modification has been linked to 
increase the risk of colorectal cancer. Two modifiable risk factors ,which 
are also interrelated to each other , are physical inactivity and excess 
body weight. These two factors  account for about one fourth to one  third 
of colorectal cancers. There is also abundant data to support , that higher 
levels of physical activity are associated with  lowered risk of cancer. 
Studies have shown that dose–response effect exist, with frequency and 
intensity of physical activity inversely associated with risk of developing 
cancer. Regular physical activity and a healthy dietary habits  can help 
individuals to  decrease the risk, although the evidence is  much higher 
for colon cancers  than for rectal cancers. The biologic mechanisms 
potentially responsible for the association is that, physical activity raises 
the BMR and increases oxygen uptake  by the cells. In the long run, 
regular periods of physical activity increase the individuals metabolic 
efficiency and capacity, it as well as reduces the blood pressure and, 
prevents development of insulin resistance. In addition, physical activity 
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also increases gut motility. Physical inactivity in daily routines attributes 
to the increased incidence of boby mass index in both males and females, 
another risk factor associated with increased incidence.  
 
 
. 
ROLE OF VITAMIN D IN COLORECTAL CANCERS: 
 Prospective studies has shown that lower levels of vitamin D is 
associated with significant increase in mortality among patients with 
colorectal cancers. In systemic review and meta-analysis of around 2000 
patients with colorectal cancers, compared patients with high level and 
low levels of vitamin D. It was found that OS and disease specific 
mortality aes were better for patients with higher levels . Yet , no specific 
data exist to prove that vitamin D supplementation improves patient 
outcomes. 
 
HISTOLOGICAL CLASSIFICATION:  
More than 90% of colorectal cancers are adenocarcinomas. 
Other histological subtypes include   
 Adenocarcinoma in situ 
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 Medullary carcinoma 
 Mucinous carcinoma (colloid type) (greater than 50% 
mucinous carcinoma) 
 
 
 Signet ring cell carcinoma (greater than 50% signet 
ring cell) 
  Adenosquamous carcinoma 
 Small cell carcinoma 
 Undifferentiated carcinoma 
 Carcinoma, NOS 
 Squamous cell (epidermoid) carcinoma 
 
 
PATHWAYS OF SPREAD: 
• Lymphatic channels and lymph nodes.  
•  To liver and lung by hematogenous spread . 
•  It also has propensity to spread within the bowel wall mainly 
longitudinally. 
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PATHOGENESIS: 
Figure 5: PATHOGENESIS 
 
 
 
PROGNOSTIC FACTORS INFLUENCING SURVIVAL: 
 depth of tumor invasion - T stage of the tumor. 
 The number of regional lymph nodes involved. 
 Vascular or lymphatic channel invasion. 
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  Presence of residual tumor following surgery- it relates to positive 
surgical margins. 
  Grade of the tumor.  
  Status of  Radial margin  . 
  Following Neo adjuvant chemo radiation – presence of residual 
tumor. 
  Histology, and association with microsatellite instability (MSI). 
  
RATIONALE FOR THE PRESENT STUDY: 
 As seen already, colorectal cancers are very common in our 
country. In our institution too they constitute 10% to 15% of the cancers 
registered in the OPD. And most of them present in the locally advanced 
stages. The presently available standards of the treatment with surgery 
and concurrent chemo radiation have a dismal performance in long term 
control with overall survival at 2 years hovering around the 50% mark 
and less than 20% surviving 5 years. Various modalities are being 
devised to overcome this.  
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This is where the intensification of the treatment is considered. The long 
course neo adjuvant chemo radiation has its own toxicity profile, leading 
to treatment breaks and decreased compliance. The argument for neo 
adjuvant radiation before the loco regional treatment is that it results in 
reduction of the tumor load, thereby resulting in better loco regional 
control. Also it has been alleged that adjuvant radiation has increased risk 
of small bowel toxicity and also decreased responsiveness because the 
blood supply to the local areas would have been altered. When the same 
is given in the neo adjuvant setting, the blood circulation in these areas is 
intact and will supposedly result in better results.  
 With these understandings, there has been a renewed interest in 
addressing locally advanced rectal cancers with neo adjuvant radiation in 
the form of short course for selected patients. So the present study 
justified in addressing this question. 
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LITERATURE REVIEW: 
Before 1900, incidence of colon and rectal cancers were negligible. 
Since then , following economic development and industrialization the 
incidence has been rising dramatically. For  all rectal cancers, surgery 
remains as the primary treatment modality .Despite these curative 
resection, local recurrence  remains high. Anatomical confines of pelvis 
and the importance of preservation of  autonomic nervous system makes 
surgery very challenging. This may account for high rates of both local 
recurrence and distal relapse. 
 
Many European randomized prospective trials have shown that 
multimodality approach   results in significant better outcome. Neo 
adjuvant treatment has emerged as the standard of care and degree of 
tumor regression has become an important prognostic factor.  A multi 
modality approach including medical oncology , radiation oncology  and  
colorectal surgery is required for optimal treatment plan. 
 
 Multiple randomized trials have shown that addition of 
preoperative chemo radiation has shown significant benefit, resulting in 
increased pathological response rates and increased local control rates. 
Earlier in 1900’s ,the National Institute of Health consensus 
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recommended combined treatment modality for stage II and III rectal 
cancer, based on observation  from Gastrointestinal tumor study group 
and National surgical adjuvant breast and bowel project trials, which 
demonstrated chemotherapy along with radiation, following surgical 
resection reduces the rates of local recurrence to 33% from 55%.It has 
also shown to prolong the disease-free survival rates . 
 
ADVANTAGES OF PREOP CHEMORADIATION: 
1. Downsizing  the tumor  volume, facilitates resection and 
increase the likelihood of sphincter saving  procedures. 
2. Irradiating the tissues before surgery, which has better 
oxygenation than the postop tumor bed tissues, and may result in 
increased responsiveness to RT. 
3. Avoidance of  radiotherapy induced injury to small bowels, 
which has dropped down into the pelvis by post surgically. 
4. The irradiated structures will be removed by surgery, 
anastamosis is with healthy Colon. 
DISADVANTAGES OF POST OP RT : 
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1. Hypoxic post surgical bed makes radiation & chemotherapy less  
effective. 
2. Increased small bowels in the radiation field,is a dose limiting 
organ, and it  increases  chances of both acute and late toxicity. 
 
SWEDISH RECTAL TRIAL: 
    A major shift in preoperative radiotherapy was brought by 
Swedish rectal trial in the year 1997. This study had 1168 pts, 
randomisied to  one of the arms , either  single week of RT followed by 
surgery, or  only surgery. On comparision of results , patients who 
received preoperative Radiotherapy  had decreased local recurrence rate 
11% vs 27%,
(5) 
and improved overall survival 58% vs 48%. On long  term 
follow up of 13 years, local recurrence and overall survival was 9% vs 
26% , and 38% vs 30%
(6).
This study concluded that preoperative 
radiotherapy in a single week immediately followed by  surgery for rectal 
cancer is found to be beneficial in terms of overall survival and cancer-
specific survival and decrease in local recurrence rates
(7)
 . 
Next came the era of TME- Total Mesorectal Exicision, which is a 
sharp dissection along the planes of visceral and parietal endopelvic 
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fascia. It also involves removal of regional lymph nodes, while preserving 
the autonomic nerves. Multiple cohort and retrospective studies have 
shown that Total Mesorectal Exicixion  is associated with lowered rates 
of pelvic recurrence compared to the less optimal blunt surgical 
dissection . 
 The Dutch TME trial ,in the year 2003 was the first trial to 
compare the results of surgey namely Total Mesorectal Exicision (TME) 
with and without short course radiation .  This trial included 1861 pts, out 
of which 924 were randomized to receive either preoperative radiation 
followed by TME, 937 were randomised to TME alone. Analysis has 
shown that , local recurrence was significantly less in patients, who 
received preoperative RT plus TME compared with surgery alone (2.4% 
vs 8.2%, P < 0.001),
(8)
 but there was not much difference in OS between 
the two groups. Sub group analysis  also proved to be favourable to 
preoperative RT arm, showing decrease in local recurrence rates  
especially in patients with nodal positivity,
(9) 
tumors located between 5-10 
cm proximally from the anal verge, and patients with negative CRM- 
circumferential resection margins. 
 
  The German CAO/ARO/AIO 94 trial compared preoperative 
short course radiation and postoperative long-course chemo radiation . It 
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included T3 or T4 and/or node-positive tumors in locally advanced rectal 
cancers . Chemo radiotherapy consisted of continuous infusional 
fluorouracil (100mg/m2 per day for 5 days in the 1
st
 and 5
th
 week of 
radiation) of 50.4 Gy in 1.8 Gy/# in  28fractions.401 and 402 patients 
were randomisied to receive preoperative and postoperative chemo 
radiotherapy, respectively .Local recurrence in the preoperative group 
was 6% and 13% in postoperative group (P = 0.006).
(10) 
Assessment of 
acute and long term toxicities have shown that  Grade 3 or higher  
toxicity occurred substantially lesser in patients who received pre 
operative chemo radiation than post operative group. P value was (P = 
0.001 and P = 0.01, respectively). (11)The main inference from the study 
has shown that the rates of sphincter preservation, Disease Free Survival 
and Overall Survival did not differ  much between the two groups. 
 
 Another comparision between long and short course radiation 
regimen  was done by Polish randomized study, which included  
patients with T3 and T4 rectal cancer. The results has shown promising 
rates of complete pathologic response in the group of patients receiving 
long- course chemo radiotherapy: 16% vs 1%  of patients had complete 
pathologic response in the long-course and short-course arms 
respectively.
(12)  
This study also showed that the sphincter preservation 
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rates were similar in both groups irrespective of the complete 
pathological states. Regarding the status of CRM- patients receiving long-
course chemo radiotherapy had only 4% compared with 13% in the short-
course group (P = 0.017
).(13)
 Inspite of the higher positive CRM rates in 
short course arm, there was not much significant differences  in rates of 
local recurrence, DFS or OS. 
 
The MRC CR07 and NCIC-CTG C016, is a  randomized trial in 
olving multiple centres. The population  study comprised 1350 patients 
comparing  the outcomes of preoperative short-course RT followed by 
surgery , and postoperative chemo radiation in selected  patients with 
positivity  of Cicumferrential Resection Margin. The outcome studied 
primarily  was local recurrence.  It demonstrated a substantial  decrease in 
rates of local recurrence between patients receiving preoperative short-
course regimen   with hazard ratio 0.39( P < 0.0001
) (13).
 And this was 
associated with a 6% absolute improvement in DFS at 3 years (P = 
0.03)
(14).
These data again demonstrate the superiority of preoperative 
chemo radiotherapy. 
 
In a review by Trans-Tasman Radiation Oncology Group Trial 
01.04,randomized Trial of Short-Course regimen Versus  conventional 
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Long-Course Chemo radiation comparing rates of local recurrence in 
Patients With T3 Rectal Cancer has shown that incidence of LR were 
7.5%
(15) 
for Short course RT and 4.4% for long course RT at the end of  3 
years . But the p value was not significant. (16) 
 
 
HYPOFRACTIONATED RADIATION: 
 The paucity of data regarding the optimal use of hypofractionated 
radiotherapy in rectal cancer for a population where 60% to 70% of cases 
usually present with locally and very advanced stages has been the idea 
behind the study protocol. 
 
 Hypofraction implies use of larger ose per fractionation with lesser 
number of fractions so as to deliver the equivalent biological effective 
dose (BED ) in a shorter duration of time. The increase in dose per 
fraction (df) over the reference value of 2Gy , for an isoeffect , the total 
dose should be reduced. Due to low     ratio curves for late responding 
tissues, the curves are steeper than those of early reactions and for 
tumors, which have a high     ratio. Hence if df is increased to 5 Gy per 
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fraction and considering the     ratio for late reacting tissues to be 3Gy , 
then the total dose must be reduced from its reference value. 
 
 Hypofractionated schedules have the advantage of being more 
convenient for the patient , their care givers and also for the health care 
providers by sparing the essential resources. 
 
POST NEOADJUVANT CHEMORADIATION LEVEL: 
It has been shown by various studies that after neo adjuvant chemo 
radiation, CEA levels of <2.5 ng/mL and 5 ng/ mL
(17)
 are associated with 
improvement in  DFS and OS. But few other , studies has discerned this 
relation. Many studies focusing on correlation between predictive factors 
and long term outcomes do not rely on CEA levels. 
(18)
So using  this 
parameter to predict  disease recurrence and survival still  remains 
inconclusive. 
 
RESPONSE ASSESSMENT AFTER NEOADJUVANT 
CHEMORADIATION: 
  The pathological response of tumor to neo adjuvant chemotherapy 
has shown to be the most  important prognostic factor in terms of rectal 
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cancer recurrence.
(19) 
Pathological Complete Respone is most strongly 
correlated with best outcomes .Many tumor regression grading systems 
are proposed and demonstrate a strong association between complete 
pathological response and their outcomes. Neo adjuvant chemo radiation 
reduces lymph node yield during surgery. The ratio of positive number of  
lymph nodes to total lymph nodes dissected  is prognostic and presence of 
positive lymph node after neoadjuvant treatment is associated with poor 
prognosis
(20).
 
 
The MERCURY TRIAL has studied the diagnosic importance of 
predicting the circumferential margin status by MRI. 
(21)
The high 
resolution MRI accurately predicts the surgical margin status involvement 
by tumor. This study has shown the importance of  identifying the 
patients with potentially affected margins and need for treating them with 
preoperative chemo radiation
 
(22). 
 
 
SURGERY: 
The concept of total mesorectal excision  in rectal cancer surgery 
has revolutionised  the modern era of treatment . the practice of  TME  
has reduced  the rate of local recurrence and tumour associated mortality 
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and morbidity.The  procedure  involves the removal of the rectal tumour 
along with the entire mesorectum (radial margin). The mesorectum is the 
fatty tissue surrounding the rectum that contains the lymph nodes and 
main blood vessels that supply the rectum.  Most of  the  local recurrence 
is likely to occur in the mesorectum, so removing the entire mesorectum,t 
reduces the chance of recurrence
(23).
 
 
The healthy end of sigmoid colon is attached to the anal sphincter 
so normal bowel function can be resumed. Sometimes the anal sphincter 
cannot be saved and a permanent colostomy is needed. The location of 
the tumour, the size of the tumour and how far away the tumour is from 
the anal verge will determine whether the TME operation is done using 
either a low anterior resection or an abdominal perineal resection. 
 
LOW ANTERIOR RESECTION (LAR): 
A low anterior resection (LAR)is a procedure  done to remove 
tumours in the upper two-thirds of the rectum. This procedure removes 
part  of the descending colon, the sigmoid colon, all or part of the rectum 
and the mesorectum. A TME approach is used to remove the rectum and 
mesorectum. 
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ABDOMINAL PERINEAL RESECTION (APR): 
An APR is a procedure done to remove low rectal tumours that 
invade the muscles around the anus. APR is also done when it is not 
possible to preserve the anal sphincter. This procedure removes part of 
the sigmoid colon, rectum, anus, mesorectum and anal muscles. The 
surgeon makes 2 incisions – one in the abdomen (using the TME 
approach) and one in the perineal region.  
 
Two separate incisions are needed because of the 2 areas that are 
being removed. The rectal area is removed through the abdomen and the 
anal area is then completely removed and stitched up. Patients will then 
have  a permanent colostomy. For this reason, APR is only done when 
there is no way to leave a margin of healthy tissue below the tumour 
margin
(24).
 
 
 
LAPAROSCOPIC SURGERY FOR LOCALLY ADVANCED  
RECTAL CANCER: 
Feasibility of laparoscopic surgery in the management rectal 
cancers has not been proven yet. But still, it has not become the standard 
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of care. The United Kingdom Medical Research Council Trial has 
compared conventional and laparoscopic assisted surgery in colorectal 
cancers. It has demonstrated equivalent results in terms of local control 
and survival benefit
.(24)
 But the operating time is significantly longer and 
estimated blood loss is less in laparoscopic surgery as compared to open 
surgery. The positivity rates of circumferential resection margin was not 
significantly different between the studied groups
(25).
  The long-term 
outcomes of patients in this trial are awaited. 
 
DISTAL RESECTION MARGIN (DRM): 
   The standard guideline recommendation for distal resected 
margin is 4- 5cm, measured  from the distal edge of tumour. Many 
studies have shown that DRM <2 cm does not increase the recurrence 
rates or have a negative impact on the survival
(26).
 In situations of low 
rectal cancers located < 5 cm from the anal verge, 1 – 2 cm may be an 
acceptable margin. 
  Following treatment with neo adjuvant chemo radiation, the  
necessity of a margin for distal rectum of 2 to 3 cm is less significant than 
CRM
.(27) 
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CICUMFERRENTIAL RESECTION MARGIN: 
The  standard cut- off point for the Circumferrential Resection 
Margin is still a matter of debate. Many studies has revealed <= 1mm 
margin as an acceptable cut off point
(29 -31).
 All have reported a 
significantly high rates of  local recurrence and decreased survival in 
patients with inadequate CRM <= 1 mm
.(32- 34) 
 
TIMING OF SURGERY AFTER NEOADJUVANT TREATMENT: 
 After long course neo adjuvant  chemo radiation ,  surgery is done 
usually after 6 weeks . This waiting period for 6 weeks is needed for 
adequate response to treatment to occur. But in case of short course 
radiation with high dose , surgery is usually done within 10 days of 
radiation. 
(35)
Maximum within fourteen days radiation toxicity sets in. 
The irradiate bowel is removed during the surgery. 
 
 
POST OPERATIVE CHEMOTHERAPY:  
For locally advanced rectal cancers- stage II and III, the risk of 
local recurrence and metastasis remains high if only treated with surgery. 
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So  to eradicate the micrometastasis, the role of adjuvant chemotherapy 
becomes crucial. 
 
Most of the data on adjuvant chemotherapy regimens comes from 
extrapolating trials on colon cancer.  The  MOSAIC TRIAL was 
conducted on stage III colonic cancers .Chemotherapy regimen FOLFOX 
4  as compared to 5FU+leucovorin has shown increase in DFS and OS
.(36)
  
In X-ACT study , the efficacy of capecitabine was compared with 5FU+ 
leucovorin , and it  has shown equal efficacy in  DFS and OS
.(37)
 
 
EVALUATION OF MESORECTUM: 
 The completeness of TME should be evaluated by the pathologist. 
The sleeve of mesorectum to be examined completely for its quality of 
resection.It is mainly for distal 2/3 rd of rectal cancers. 
 
 
 
TREATMENT DURATION TIME: 
 With long course of radiation , the time period  required for neo adjuvant 
chemo radiation is 5.3 weeks. Patient has to wait for 6 weeks before 
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surgery. Then adjuvant chemotherapy is given after 3  to 4 weeks 
following surgery. So the total treatment time is around 40 weeks till 
completion of adjuvant 6 cycles chemotherapy. 
 With short course radiation, the time required for radiation is one 
week. Surgery is done usually within 10 days of radiation. Adjuvant 
chemotherapy is given 3 -4 weeks following surgery. So the total 
treatment time is around 27 weeks. The significance of short course 
radiation is shorter duration of treatment and hence better patients 
compliance to treatment schedule. 
   Treatment breaks which occur during long course chemo radiation 
also has negative impact on local control of the disease and long term 
survival. Most of the patients default during the course of chemo 
radiation too, because of acute toxicities like cystitis and diarrhoea. 
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LONG COURSE CCRT REGIMEN: 
     Diagnosis , investigation evaluation of treatment plan  
 2 WEEKS 
 
    Concurrent chemo RT 50.4 Gy / 1.8 Gy/ # X 28 # 
  6WEEKS                            + 
Chemotherapy= Capecitabine/Infustional  5FU/ Bolus 5 FU +     
Leucovorin 
 
             6WEEKS    Waiting period before surgery 
 
  
Total  Mesorectal Excision 
            LAR/ APR 
             6WEEKS         
                           Adjuvant chemo therapy 6 cycles 
                                   CAPEOX regimen 
          18 WEEKS        for 6 cycles of chemo therapy  
Totally : 36 to 40 weeks of treatment. 
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               SHORT COURSE RADIATION REGIMEN: 
     Diagnosis , investigation evaluation of treatment plan  
 2 WEEKS 
 
   Short course radiation hypofraction 5Gy / # X 5 # = 25Gy 
    
         
            7 to 10 days    Waiting period before surgery 
 
  
Total  Mesorectal Excision 
            LAR/ APR 
             4-5WEEKS         
                           Adjuvant chemo therapy 6 cycles 
                                   CAPEOX regimen 
          18 WEEKS        for 6 cycles of chemo therapy 
Totally : 25 to 26 weeks of treatment 
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PREOPERATIVE VS POSTOPERATIVE RADIATION: 
Main  advantages of preoperative radiation , as compared to 
radiation given in the postoperative period are related  to both response of 
tumor tissues and preservation of normal tissues. Although some trials 
have indicated that preoperative radiation or chemo RT is asscociated 
with increased sphincter preservation rates, but recent meta analysis of 
randomisied trials do not support it. (38)This may be due the surgeons 
perspective of removing the microscopic disease left behind after tumor 
downsizing. It also implies a good oncological practice . 
 
CONCURRENT CHEMOTHERAPY WITH RADIATION: 
 Many randomized trials have studied the effectiveness of adding 
chemotherapy to radiation administrating either preoperatively or 
postoperatively. The benefits of adding chemotherapy either with pre or 
post operative radiation has increased the , local radiation sensitisation 
and systemic control of diseases (ie) the eradication of micro metastasis
(39 
– 41)
 .    
 
A recent  Cochrane review of six randomizied control studies 
showed that adding chemotherapy to preoperative radiation in resectable 
stage II/ III rectal cancers enhances the pathologic response rates and 
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improves the local control rates. But it did not have any effect on the 
overall survival, 30 day mortality , sphincter preservation  rates and late 
toxicity(42-45). 
 
 KRAS MUTATION: 
 Approximately 40% of patients with colorectal cancers have 
mutations in the genes encoding KRAS. The presence of mutations in 
codons 12 and 13 in exon 2 o f KRAS gene  predicts the 
nonresponsiveness to EGFR  inhibition.  Hence patients presenting with 
metastatic colorectal cancers, being considered for anti EGFR therapy 
should have their tumor tissue genotyped for presence of KRAS mutation 
before initiation of treatment. Several studies has shown that targeted 
agents produce negative impact on survival ,in patients with mutaed 
KRAS. So patients with KRAS mutation or NRAS mutation should not 
be treated with targeted either cetuximab or panitumumab. 
 
 Studies on colorectal cancer formation has shown that KRAS 
mutation occurs as an early event. Therefore a strong correlation exists 
between the mutation status , primary tumor and metastasis. It has been 
found that KIRSTEN RAS  ( KRAS) – mutation was associated with poor 
survival rates than patients with wild type KRAS . Presence of V600 
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BRAF  mutation also signifies poor prognosis too. Data is insufficient to 
approve the use of anti EGFR  therapy in the first line setting with 
systemic chemotherapy. 
 
According to PRIME study , panitumumab was used along with 
FOLFOX  regimen. It was used as a first line treatment in colorectal 
cancers. The results of this study showed that in patients with mutated 
KRAS , panitumumab had de trimental effects. 
 
MICRO SATELLITE INSTABILITY:(MSI) 
Testing for MSI should be considered for patients <= to 70 years of 
age  with colorectal cancers.It should also be done on patients who are > 
70 years of age , but meeting the Bethesda guidelines. 
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AIMS AND OBJECTIVES: 
The aim of this study was to evaluate the efficacy of neo adjuvant 
short course Radiotherapy  followed by surgery in locally advanced rectal 
cancers. 
 
Primary Objectives : 
To assess the   immediate loco regional response rates of  
resectable stage II/III rectal cancers with   neo adjuvant short course 
radiotherapy followed by  surgery within 10 days. 
 
Secondary objectives: 
To assess acute toxicity to neo adjuvant short course radiation in 
locally advanced rectal cancer. 
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MATERIALS AND METHODS: 
 
STUDY DESIGN: 
This was a Single arm prospective study with a Phase III design. 
 
STUDY DURATION: 
OCTOBER, 2014 – August, 2015 
 
STUDY CENTRE:  
Department of Radiotherapy, Barnard Institute of Radiology & 
Oncology, Madras Medical college, Chennai. 
 
SAMPLE SIZE:  
30 consecutive patients with histopathologically proven 
adenocarcinoma of rectum who fulfilled the inclusion criteria were 
recruited in the study from the outpatient department. 
 
The intent of treatment was to be radical, aiming for cure, considering 
their disease stage, co- morbidities and performance status. 
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ETHICAL COMMITTEE APPROVAL:  
Approval from the institute ethical committee was obtained on 
07.10.2014. 
 
INFORMED PATIENT CONSENT:  
All patients enrolled in the study were informed about the merits 
and demerits of participating in this study and signed an informed consent 
form in their regional language, which is Tamil. 
 
METHODOLOGY: 
 Eligible patients will be treated with hypofractionation 5Gy per 
fraction for 5 days in one week, followed by surgery after 2 weeks. 
Postoperatively adjuvant chemotherapy is given for 6 cycles. The 
response to treatment and acute toxicity is to be assessed periodically. 
 
Inclusion Criteria: 
• Biopsy proven newly diagnosed adenocarcinoma  of rectum.  
• Age 18 - 65 years.  
• T3 lesions less than or equal to 5 cm,N0 OR N+ disease. 
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• Performance status ECOG 0-2.  
• Medically manageable co-morbidities. 
• Signed informed consent prior to initiation of protocol. 
 
Exclusion Criteria: 
• Histopathology other than adenocarcinoma . 
• Inadequate hepatic and renal functions, bone marrow reserve. 
• Uncontrolled co-morbidities. 
• Patient not consenting to radiotherapy/ surgery/chemotherapy at 
any point in the treatment.  
• Previously received  treatment for any other malignancy. 
 
Sample Size: 30 patients 
 
Investigation Details: 
 
• . Detailed history elucidation. 
•  Complete physical examination by inspection, palpation. 
•  Biopsy from the primary tumour.  
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•  Baseline-Complete blood count, liver function test, renal function 
test. 
•  X-ray chest PA view, 
•  ECG, 
• Blood grouping &typing, 
• Cardiac evaluation and fitness.  
• Anaesthetic fitness for surgery, 
• Colonoscopy, 
•  MRI- Pelvis-Plain &Contrast pretreatment. 
• Tumor marker- CEA levels. 
• Histopathology of surgical specimen. 
 
Staging was done based on American Joint Committee staging manual 
7th edition (for colorectal cancers). 
 
PATHOLOGICAL STAGING OF THE SPECIMEN: 
1. Gross description of the tumor and specimen. 
2. Grade of the tumor. 
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3. Depth of penetration and extension to adjacent structures. 
4. 5. Number of positive Lymph nodes. 
6. Status of proximal ,distal and CRM. 
7. Neoadjuvant treatment response. 
8. LVI 
9. Perineural invasion. 
10. Number of tumor deposits. 
 
CIRCUMFERRENTIAL RESECTION MARGIN: 
It is defined as the closest radial margin , always measured in 
millimeters. It is between the deepest penetration of tumor tissue  and 
resected edge of soft tissue around the rectum. Also  from the edge of 
positive lymph nodes.CRM is identified by evaluating the outer surface 
of the resected specimen , which if often inked at. The examination of the 
specimen requires a bread loafing slicing technique.   
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TREATMENT PROTOCOL: 
An informed consent was obtained from all patients. Before 
starting treatment, it was ensured that all patients had normal 
hematological/renal parameters and normal liver function tests. Adequate 
cardiopulmonary function that could tolerate radical surgery was also 
assessed before treatment. Comorbid conditions like diabetes and 
hypertension were evaluated thoroughly and treated with appropriate 
medications. 
 
THERAPEUTIC PROTOCOL: 
 Short course radiation with  hypofractionation 5 Gy / #  X 5 #  
followed by TME within  10 days for T3 rectal  cancers. 
 
 EBRT EQUIPMENT           Co – 60 Phoenix for Teletherapy 
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SIMULATION AND TREATMENT DELIVERY 
                    The treatment field was verified with PA simulator films in 
which the distal extension of the tumor was identified by placing a radio-
opaque marker in the anal verge. The lateral portals were verified by 
lateral simulator films.The treatment plan was evaluated with and without 
wedges in TPS planning system and optimal treatment plan was selected 
from isodose pattern All patients were positioned in the prone position 
only with full bladder during external RT to exclude a greater extent of 
the small bowel from the treatment field. 
 
SIMULATION FILM  USED: 
Figure 16: Simulation Film 
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RT SCHEDULE 
All patients were treated with  hypofractionated dose 500cgy/  
#  by three field  1 PA portal( 168 cgy)  / 2 lateral portals ( 166 cgy each) 
to a total dose of  500cgy delivered from Monday, Wednesday to  Friday  
in a week . 
 
RADIOTHERAPY TECHNIQUE: 
                                 Radiotherapy was delivered by three field technique 
 to the pelvis with a telecobalt machine. 5 # was delivered in 5days in one 
week. The clinical target volume including the tumor, internal iliac nodes, 
obturator nodes , and the anal canal for adequate clearance  received the 
calculated dose of 25 Gy. Organ at risk was given due consideration in 
treatment planning process. All three fields were treated on all 5 days of 
planned radiation with equal dose distribution. 
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RADIATION MARGINS: 
 
POSTERO-ANTERIOR FIELD: 
Table 2 
RT PORTAL MARGINS  FOR EBRT PA PORTAL 
SUPERIOR L5 S1 INTERFACE 
INFERIOR 
2 CM BELOW DISTAL 
MARGIN OF TUMOR 
LATERAL 
2CM LATERAL TO BONY 
PELVIS 
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LATERAL FIELD: 
Table 3 
RT PORTAL MARGINS  FOR EBRT LATERAL PORTAL 
SUPERIOR L5 S1 INTERFACE 
INFERIOR 
2 CM BELOW DISTAL 
MARGIN OF TUMOR 
ANTERIOR 
POSTERIOR BORDER OF 
PUBIC SYMPHYSIS 
POSTERIOR PRESACRAL BAY – S2 
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BED VALUE CALCULATIONS FOR EBRT  :  
According to the linear –Quadratic  model the formula for 
calculating the biologically effective dose is 
 
BED =Nxd [1+d/(/)] –K[T-T0] 
 
 
 
Where   N  -  no of fractions 
d   - dose per fraction 
/  -dose at which the linear and quadratic cell kills are equal 
k  -constant (Dose required /day to counter act proliferation) 
          T  - Over all treatment  time                          
         T0 – Onset time for proliferation  
 
 
 
 
51 
 
Calculation of biologically equivalent doses to 2 Gy /#  for the three most 
commonly used fractions. 
Table 4 
Biologically equivalent doses to 2 Gy / # 
 25 Gy in 5Gy/# 45 Gy in 25 # 50.4 Gy in 28 # 
Tumor control 
with 
Time correction 
35.7 28.1 30.4 
Late issue 
toxicity 
40.0 43.2 48.4 
 
 
Biologically equivalent doses (2 Gy per fraction) along with a factor 
for time correction = biologically equivalent doses (2 Gy per fraction) 
– 0.6 Gy ( T-7 ), 
Where T = overall treatment time in days. 
In this equation ,it is assumed that 0.6 Gy is lost per day due to 
tumor repopulation starting after 7 days from the beginning of radiation. 
 
 
52 
 
RESPONSE EVALUATION AND SURGERY 
Within 10 days of last fraction of radiation, patients are taken up 
for surgery- TME either low anterior resection or abdomino perineal 
resection. Histologic analysis of surgical specimens was done to assess 
the extent of CRM-circumferrential resection margin status ,lymph node 
status and the involvement of proximal and distal rectal margins. 
Operative complications included bladder, small bowel, ureteral or 
vascular injuries. Any surgery related adverse event occurring within 
30days from the intervention was recorded as postoperative complication.  
 
TOXICITY ASSESSMENT:  
Patients were reviewed every day before radiation for any acute 
toxic reactions. Reactions like skin desquamation, cystitis, and proctitis 
etc. were recorded and graded based on RTOG acute radiation morbidity 
criteria. Careful attention was given for maintenance of hydration, 
adequate dietary intake and good personal hygiene.  
  Hematological and renal parameters were assessed before and after 
radiation. And before surgery. Anaesthetist opinion was  obtained.  
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SIDE EFFECT MANAGEMENT: 
 In female patients , symptoms of vaginal stenosis can occur. So 
they should be instructed to use vaginal dilators . 
 In case of young males and females, counselimg should be done 
regarding infertility risks. They should be given information 
regarding sperm and oocyte banking. 
 
 
STATISTICAL ANALYSIS:  
The patient factors, tumor factors, response to treatment, and 
toxicities were thoroughly analyzed. The results are expressed in 
percentage. Since this  study is single armed one and also the sample size 
was only 30, the levels of significance cannot be commented on. 
 
FOLLOW UP: 
 Patients after completion of surgery was discharged from the 
hospital and was to review  after 4 weeks for adjuvant 
chemotheraphy.  
 CEA levels were done after surgery and there after three monthly. 
 Imaging was done when indicated clinically 
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 Counselling to the patient and attender, rehabilitation, usage of 
colostomy bags and cleaning of the same was given.  
 
MANAGEMENT OF LATE SEQUELE OF TREATMENT: 
 Patients treated with pelvic surgery and radiation can have 
symptoms of chrnic diarrhea or incontinence. They should be managed 
symptomatically with anti- diarrhea drugs, stool bulk forming agents, diet 
manipulation and protective undergarments. Radiation cystitis , increased 
frequency and urgency of micturation are managed symptomatically with 
bladder irrigation techniques.  
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TREATMENT PROTOCOL 
Patient Selection 
Based on inclusion criteria 
 
 
Pretreatment evaluation including blood investigations,imaging , 
biopsy 
 
Treatment administration- neoadjuvant short course RT 
5Gy/#  X 5# in one week 
 
Regular monitoring of toxicities 
Treatment  completion 
Surgery within 10 days TME 
 
Review with pathology report for response assessment 
 
Adjuvant chemotherapy 6 cycles CAPEOX 
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RESULTS AND ANALYSIS 
Out of  30 patients recruited for the study, 29 pts completed their 
entire treatment protocol and were available for analysis of results. One 
patient underwent diversion colostomy only, followed by palliative 
chemotherapy. 
 
PATIENT CHARACTERISTICS: 
AGE DISTRIBUTION: 
   43% of the patients belonged to the age group 51- 60yrs, followed 
by 41 -50yrs. The mean age of presentation was 55.5yrs. The youngest 
patient age was 35yr   and the oldest was 67 yrs. 
 
AGE DISTRIBUTION OF THE STUDY POPULATION 
Table 5 
 
AGE GROUP 
 
NUMBER 
 
PERCENTAGE 
 
31- 40yrs 
 
6 
 
20% 
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GENDER: 
The gender distribution in the study population is dominated male 
population. This study has 16 male patients followed by 14 female 
patients. 
GENDER DISTRIBUTION OF THE STUDY POPULATION 
Table 6 
 
SEX 
 
NO. OF PATIENTS 
 
PERCENTAGE 
 
MALE 
 
16 
 
53.33% 
 
FEMALE 
 
14 
 
46.67% 
 
 
41 -50yrs 
 
9 
 
30% 
 
51-60yrs 
 
13 
 
43% 
 
61-70yrs 
 
2 
 
7% 
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PERFORMANCE STATUS:  
All patients in this study had a general performance status of 
ECOG (Eastern Cooperative Oncology Group ) grade 0 or 1. 
 
 
ECOG PERFORMANCE STATUS 
Table 7 
 
ECOG 
 
NO.OF PATIENTS 
 
PERCENTAGE 
 
ECOG 0 
 
18 
 
60% 
 
ECOG 1 
 
12 
 
40% 
 
 
 
SYMPTOMS AND SIGNS: 
 Among the study patients the most common presenting symptom 
was bleeding per rectum followed by difficulty in defecation.(figure no:6 
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SYMPTOMS/SIGNS 
Table 8 
 
PRESENTING 
SYMPTOMS/SIGNS 
 
NUMBER 
 
PERCENTAGE 
PAIN DURING 
DEFECATION 
 
12 
 
40% 
BLEEDING PER 
RECTUM 
 
16 
 
53% 
DIFFICULTY IN 
DEFECATION 
 
18 
 
60% 
LOWER ABDOMINAL 
PAIN 
 
12 
 
40% 
INCREASED 
FREQUENCY OF 
STOOLS 
 
7 
 
23% 
 
LOSS OF WEIGHT 
 
4 
 
13% 
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HISTOLOGICAL DIFFERENTIATION: 
 Most of the patients in the study belonged to moderately 
differentiated histology followed by well  differentiated on 
 
HISTOLOGICAL DIFFERENTIATION 
Table 9 
 
HISTOLOGICAL 
DIFFERENTIATION 
 
NUMBER OF 
PATIENTS 
 
PERCENTAGE 
 
WELL 
DIFFERENTIATION 
 
9 
 
30% 
 
MODERATELY 
DIFFERENTIATED 
 
16 
 
53.33% 
 
POORLY 
DIFFERENTIATED 
 
5 
 
16.67% 
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SIZE OF THE TUMOR: 
The estimation of tumor size was by clinical and radiological 
examination. Imaging modality used was MRI . 
 
SIZE OF TUMOR 
Table 10 
 
.   
As per the inclusion criteria, only patients having size of the tumor mass 
less than 5 cms were included. 50 % of them had tumor size between 2- 4 
cms and 50 % of them between 4 – 5 cms. 
 
 
SIZE OF THE TUMOR 
 
NO. OF PATIENTS 
 
2-4cm 
 
15 (50%) 
 
4– 5 cm 
 
15 (50%) 
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 HISTOLOGIC  GRADE: 
 Most common histological grade was grade II , followed by grade 
I tumors. 
HISTOLOGICAL GRADE 
Table 11 
 
         GRADE 
 
NO. OF PATIENTS 
 
GR I 
 
11( 36.67%) 
 
GR II 
 
  12 (40%) 
 
GR III 
 
7 ( 23.33%) 
                                              
TYPE OF SURGERY: 
 Out of 30 patients , 29 underwent curative resection. One patient 
had only diversion colostomy due to adherence to adjacent structures.40 
% of patients underwent Low anterior resection.56% of patients had 
Abdomino perineal resection. Selection of patients for either of the 
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procedures was  based on  distance of the tumor from anal verge  and also 
the oncological principle of achieving adequate distal margin status and 
TYPE OF SURGERY 
Table 12 
 
TYPE OF SURGERY 
 
NUMBER 
 
PERCENTAGE 
 
Low anterior resection 
 
12 
 
40% 
 
Abdominoperineal 
resection 
 
17 
 
56.67% 
 
Hartmans procedure 
 
1 
 
3.33% 
 
 
STATUS OF CIRCUMFERENTIAL RESECTION MARGIN: 
All patients had adequate circumferential resection margin status. 
None of them had positivity of CRM less than one centimeter. 
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CIRCUMFERRENTIAL MARGIN STATUS 
Table 13 
 
CIRCUMFERRENTIAL 
RESECTION MARGIN 
 
NO.OF 
PATIENTS 
 
PERCENTAGE 
 
< =1  CM 
 
NONE 
 
O% 
 
>1  CM 
 
29 
 
  96.67% 
 
 
PATHOLOGICAL T STAGE: y p (T) stage 
 For patients who had minimal involvement of perirectal tissues, 
after neoadjuvant radiation they were downstaged to T2 lesion from T3 
lesion. 
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Y P( T ) STAGE 
Table 14 
 
TUMOR STAGE 
 
NO.OF PATIENTS 
 
PERCENTAGE 
 
T2 
 
9 
 
30% 
 
T3 
 
20 
 
66.67% 
 
 
 
DISTANCE OF LOWER BORDER OF TUMOR FROM ANAL 
VERGE: 
 Most of the tumors were 3 to 6 cms from the anal verge, around 
46.67 percent.  26.67 5 of the patients had tumors in the upper part of the 
rectum , with distal margins more than 6 cms from the analverge. 
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DISTANCE FROM ANAL VERGE 
Table 15 
 
DISTANCE FROM 
ANALVERGE 
 
NUMBER OF 
PATIENTS 
 
PERCENTAGE 
 
0 – 3 cms 
 
8 
 
26.67% 
 
 3 – 6 cms 
 
14 
 
46.67% 
 
 > 6 cms  
 
8 
 
26.67% 
 
 
NO OF RETRIEVED MESORECTAL LYMPHNODES: 
   Yield of lymph nodes in the mesorectum  after neoadjuvant 
treatment is usually less compared to afferent surgery. Median number of 
lymph nodes resected was 7 LNs.  
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NUMBER OF LYMPH NODES DISSECTED 
Table 16 
 
NO OF NODES 
DISSECTED 
 
NUMBER OF 
PATIENTS 
 
PERCENTAGE 
 
   0 – 5 
 
11 
 
36.67% 
 
   5 – 10 
 
13 
 
43.33% 
 
   > 10 
 
5 
 
16.67% 
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NODAL STATUS: 
 Nodal staging after neoadjuvant  radiation is usually difficult. 60% 
of the patients had N0 disease. 
 
NODAL STAGING. 
Table 17 
 
NODAL STATUS 
 
NO.OF PATIENTS 
 
PERCENTAGE 
 
N0 
 
18 
 
60% 
 
N+ 
 
12 
 
40% 
 
 
 
INTERVAL BETWEEN RADIATION AND SURGERY: 
 Most of the patients were taken up for surgery within  10 days. 
Median number of days between last day of radiation and surgery is 8 
days 
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TUMOR SIZE Vs RESPONSE 
Table 18 
Tumor size 
 
Response 
 
CRM 
1-1.5 CM 
 
CRM 
>1.5 CM 
 
T2  
DISEASE 
 
2-4 CM 
 
2 
 
4 
 
9 
 
4- 5 CM 
 
10 
 
4 
 
        - 
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RESPONSE VS ISTANCE FROM ANAL VERGE 
Table 19 
 
DISTANCE FROM ANAL 
VERGE 
 
Response 
CRM 
1-1.5 CM 
 
CRM 
>1.5 CM 
 
T2  
DISEASE 
 
0 – 3 CM 
 
5 
 
2 
 
0 
 
3 – 6 CM 
 
4 
 
3 
 
7 
 
> 6 CM 
 
3 
 
3 
 
2 
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 HISTOLOGICAL DIFFERENTIATION Vs RESPONSE 
Table 20 
HISTOLOGIC 
DIFFERENTIATION 
 
Response 
CRM 1-1.5 
CM 
 
CRM >1.5 
CM 
 
T2 
DISEASE 
 
WELL DIFFERENTIATED 
 
3 
 
3 
 
3 
 
MODERATELY 
DIFFERENTIATED 
5 5 
 
6 
 
POORLY 
DIFFERENTIATED 
4 - 
 
- 
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PERFORMANCE STATUS Vs RESPONSE: 
 The ECOG performance status among the study patients did not 
show much difference in the response rates, as the study patients are in 
the ECOG 0 OR ECOG 1. 
 
 
GENDER Vs RESPONSE: 
As the male population dominated the study 75% of the males had 
complete response in contrast to 66% of the females. As the male and 
female ratio was not equivalent it cannot be considered as significant. 
 
 
TREATMENT RELATED ACUTE TOXICITIES: 
        As expected with pelvic radiation , toxicity to bladder , small bowel 
and pelvic bone marrow was not seen in this study. Mainly these type of 
complications occur during long course radiation. 
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SYSTEMIC TOXICITY: 
 The treatment related systemic toxicity was assessed with CTCAE 
V 4.03 and treated accordingly. Most of the patients experienced nausea 
and diarrhea. 
 
 
NAUSEA:  
 80% of the study population developed loss of appetite grade 1 
nausea during their treatment course.20% of them developed grade 2 
nausea. 
 
 
VOMITING: 
 23% of the patients had  grade 1(1 or 2 episode) of vomiting during 
radiation. Only 6% of the patients had grade 2(3 or 4 episodes) of 
vomiting managed by Oral Rehydration Salt and Inj.Ondansetron iv bid 
for 3 -5 days. Intravenous fluids were given whenever necessary. 
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DIARRHOEA: 
 Only 30% of the patients had grade 1 diarrhoea *(many of them 
had preexisting diarrhea). Mostly the diarrhea was managed 
conservatively.  
 
SYSTEMIC TOXICITY 
Table 21 
 
TOXICITY 
 
GRADE I 
 
GRADE II 
 
NAUSEA 
 
24  
 
6 
 
VOMITING 
 
7 
 
2 
 
DIARRHOEA 
 
9 
 
4 
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NAUSEA:  
 Since the radiation included only the pelvic cavity , and not much 
of small bowels into the field , few patients had nausea and vomiting. it 
was managed conservatively with  
      1.IV fluids to correct dehydration, if any. 
2.Metoclopramide 40 mg PO every 4–6 hours for 4 days.  
3.Ondansetron 4-8 mg IV BD for 4 days.  
 
 
DIARRHOEA: 
 Diarrhea is a common complication in any pelvic radiation  
regimen. The grade 1 and grade 2 reactions were managed by plenty of 
fluid intake, and IV fluids in case of dehydration not corrected by oral 
rehydration alone. Antispasmodics and anti-motility agents were used to 
reduce the frequency of stools and to manage the abdominal cramps and 
pain. Regular monitoring of the biochemical parameters was done.  
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DISCUSSION: 
 Although radiation has been associated with decreased rates of 
local recurrence in rectal cancers, it is also associated with increase in 
toxicity, compared to surgery alone. Hence patients with disease at the 
lower risk of local recurrence,,like small volume disease, T3 N0 M0 , 
proximal rectal tumors may be adequately treated with short course 
radiation. 
 
The results of the present study show that neo adjuvant radiation in 
the form of short course therapy is feasible in our setup and should be 
considered in select cases of locally advanced rectal cancers. The study 
included a wide range of patients across the age groups between the 
eligibility ages of 18 years to 70 years. The study population was mostly  
males 16 patients with females 14 patients. 
 
All the patients started on the protocol completed the course of 
radiation.  But only 29 patients went in for curative resection which is 
TME .This one single patient had only a diversion procedure. It was 
because of adherence of tumor to adjacent structure. This implies 
indirectly that it is important to select cases carefully for this regimen. 
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The compliance of the patients to radiation was very good , since 
the radiation was  only  for 5 day. But few patients were reluctant  to 
undergo permanent colostomy. So both the patients and the family 
members were to be counseled for it. Few patients were quite depressed 
following colostomy, they were given continuous support and 
rehabilitation during the further course of adjuvant treatment.   
 
The patients should be counseled clearly before discharging from 
the hospital, the essential part of adjuvant chemo therapy and the  right 
time patients had to return for the benefits of chemotherapy. Probably 
literacy will play a major role in this regard with literate people being 
able to grasp the consequences of defaulting adjuvant chemo therapy. 
Differentiation which is probably a surrogate for the mitotic rate of the 
tumor cells showed a significant correlation with response rates. 
Moderately differentiated tumors had a good response in terms of 
adequate reduction in tumor size as compared to other degrees of 
differentiation. It is a known fact that the T size of the primary tumor will 
have an impact on the immediate loco regional control as well as the 
recurrence free survival. The present study has confirmed the same fact 
with T size smaller tumors achieving more  good responses.  
 
78 
 
In the present study too , tumors located more proximal to anal 
verge achieved adequate tumor regression , as evidenced by change in the 
T stage from T3 to T2. Polish randomisied  trial and has shown that Long 
course is better to short course for more distally located tumors in terms 
of achieving adequate tumor downsizing and negative surgical margins. 
 
So one must be precise in selecting cases for short course radiation. 
Patients must be selected on the basis of tumor T stage – T3, no nodal 
disease. The location of tumor from anal verge is also important in patient 
selection. More distal tumors should be treated with long course and 
proximally located tumors with short course. Preoperative assessment of 
tumor tethering and fixity should be considered for choosing between 
these two radiation regimens. Nodal status at the time of diagnosis plays a 
crucial role in deciding the treatment options. Nodal positivity warrants 
long course chemo radiation. 
 
The Swedish rectal cancer trial demonstrated that short course 
preoperative radiation reduced the risk of local recurrence by half. 
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The Dutch rectal cancer trial showed that short course 
preoperative radiotherapy provides a definite benefit when it is combined 
with the best surgical approach – Total Mesorectal Exicision. 
The German rectal cancer trial which compared pre operative 
with poat operative radiation, showed the superior benefit of pre 
operative regimen in terms of local control. 
 
The trend is consistent with the common belief that long course is 
superior to short course , for a greater downsizing of the T stage, N status. 
However the Polish trial did not show any apparent effect on APR rates 
for rectal tumors. 
 
In this meticulous study design, the value of short course radiation 
in selected patients is proved beyond doubt 
 
 
STRENGTHS OF THE STUDY: 
1. The study delivered the optimal neoadjuvant treatment in the form 
of short course radiation for selected patients. 
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2. The definitive part of the treatment, which is the surgery was done  
following the neoadjuvant  phase. 
3. The optimal adjuvant chemotherapy CAPEOX was delivered 
following surgery for a period of six months. 
4. All the toxicities were graded using standard scale Common 
Toxicity Criteria for Adverse Events Version 4. 
5. The response assessment was done using a standard scale .  
 
LIMITATIONS OF THE STUDY:  
1.  Only neo adjuvant radiation was given without chemotherapy. 
2. The radiation was delivered using 2D techniques. Delivering with 
3D conformal techniques would have been the optimal technique. 
3. There was no long term follow up of the patient which would have 
given the DFS and OS data for the sequential treatment. 
4. The present study was a single arm study. A two arm comparative 
randomized study would have been better to settle the question of 
whether short course is better to long course chemo radiation.   
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CONCLUSION: 
 In locally advanced rectal cancers neo adjuvant treatment in the 
form of chemo radiation has now become the standard of care . It has 
shown to be the effective way in improving the local control rates and 
survival of patients. To prevent under treatment or over treatment of 
patients, accurate staging of the disease is mandatory for deciding the 
treatment policy, which varies with various stages of the disease. MRI 
has a major role to play in optimally staging the disease preoperatively. 
 
 Following rectal cancer surgery, irrespective of what the 
pathological response is adjuvant chemotherapy is indicated. Six months 
of peri operative chemotherapy is now the standard of care.  
 
 Both short course and long course pre operative regimens have 
been used in parallel for more than 15 years, in most European countries. 
In our country short course radiation is not widely practised. One reason 
for more lenient usage of long course is hypothetical belief that 
hypofractionated doses are associated with more late toxicities than long 
course conventional fractionation. Secondly for the fear that short course 
may not produce adequate tumor downsizing required. Encouragement 
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should be in favour of short course radiation in select patients as 
discussed upon, with lower risk of disease.  
  
FUTURE DIRECTIONS: 
Future directions would require modulating the various 
management strategies, using different drug combinations of 
chemotherapy with targeted agents, changing the sequence of treatment 
and using newer approaches to radiation therapy. The ultimate treatment 
goal is to achieve good response rates and survival. The greatest 
challenge will be to individualise care to improve long-term oncologic 
outcome, while minimizing the treatment related toxicities and 
maintaining good quality of life. 
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 Annexure I 
Information to Participants 
Title: “NEOADJUVANT SHORT COURSE RADIOTHERAPY FOLLOWED BY 
SURGERY IN LOCALLY ADVANCED RECTAL CANCERS” 
Principle Investigator:  Dr.Madhulika vijayakumar. 
Name of Participant: 
Site: Department of Radiotherapy, Madras Medical College & RGGGH, 
Chennai-3 
You are invited to take part in this research/ study/procedure. The information 
in this document is meant to help you decide whether or not to take part. 
Please feel free to ask if you have any queries. 
What is the purpose of this study? 
 The incidence of rectal cancers has been increasing worldwide due to 
economic development and industrialization. Surgery is the primary modality 
of treatment in spite of it, local and distant recurrence rates are high.pre 
operative treatment before surgery has shown significant reduction in the local 
recurrence and distal failure rates.pre operative treatment in the form of short 
course radiation for 5 days followed by surgery has shown promising results in 
tumor downstaging and good response rates. We want to assess the 
immediate loco regional response rates and treatment related toxicity. 
We have obtained permission from the Institutional Ethics Committee. 
 
The study design:  Single arm Prospective study. 
 
Study Procedures: 
 The study involves assessment of response and toxicity in locally 
advanced rectal cancers treated with short course pre operative radiotherapy 
followed by surgery, which will need complete blood investigations, CT chest, 
MRI pelvis and assessment by surgeon &anaesthetist as a part of standard 
protocol for any other patients receiving radiotherapy. Following radiotherapy 
you will be undergoing surgery after 2 weeks .The tests are essential to 
monitor your condition, and to assess the safety and efficacy of treatment. You 
may have to come to the hospital for examination and investigations apart 
from your scheduled visits, if required.  
 
Possible risks to you: None greater than standard patients receiving 
radiotherapy. 
 
Possible benefits to you: Shorter treatment duration during time compared to 
patients treated with conventional fractions. 
 
Possible benefits to other people: The results of the research may provide 
benefits to the society in terms of advancement of medical knowledge and/or 
therapeutic benefit to future patients. 
 
 
Confidentiality of the information obtained from you: 
 You have the right to confidentiality regarding the privacy of your 
medical information (personal details, results of physical examinations, 
investigations, and your medical history).By signing this document, you will be 
allowing the research team investigators, other study personnel, sponsors, 
Institutional Ethics Committee and any person or agency required by law like 
the Drug Controller General of India to view your data, if required. The 
information from this study, if published in scientific journals or presented at 
scientific meetings, will not reveal your identity. 
 
  
 
How will your decision to not participate in the study affect you? 
Your decision not to participate in this research study will not affect your 
medical care or your relationship with the investigator or the institution. You 
will be taken care of and you will not lose any benefits to which you are 
entitled. 
 
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the 
right to withdraw from this study at any time during the course of the study 
without giving any reasons. However, it is advisable that you talk to the 
research team prior to stopping the treatment/discontinuing of procedures 
etc. 
 
 
 
Signature of Investigator                                            Signature of Participant 
                                                                        
Date                                                                                                  Date 
 
 
 
 
 
 Annexure II 
INFORMED CONSENT FORM 
 
TITLE OF THE STUDY: “ NEOADJUVANT SHORT COURSE RADIOTHERAPY FOLLOWED BY SURGERY IN 
LOCALLY ADVANCED RECTAL CANCERS.  
NAME OF THE PARTICIPANT: 
NAME OF THE PRINCIPAL(Co – Investigator ): DR.Madhulika Vijayakumar. 
NAME OF THE INSTITUTION:  MADRAS MEDICAL COLLEGE 
 
I, _____________________________ have read the information in this form (or it has been read to 
me). I was free to ask any questions and they have been answered. I am over 18 years of age and, 
exercising my free power of choice, hereby give my consent to be included as a participant in “ 
NEOADJUVANT SHORT COURSE RADIOTHERAPY FOLLOWED BY SURGERY IN LOCALLY ADVANCED 
RECTAL CANCERS ” 
 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have been informed the investigator of all the treatments I am taking or have taken in 
the past 12 months including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this study.* 
7. I agree to cooperate with the investigator and I will inform him/her immediately if I suffer 
unusual symptoms.* 
8. I have not participated in any research study within the past  12month(s). * 
9. I agree to undergo complete blood count, renal and liver function test, CT scan   chest, 
MRI pelvis. 
10. I am aware of the fact that I can opt out of the study at any time without having to give 
any reason and this will not affect my future treatment in this hospital. * 
11. I am also aware that the investigator may terminate my participation in the study at any 
time, for any reason, without my consent. * 
12. I hereby give permission to the investigators to release the information obtained from me 
as result of participation in this study to the sponsors, regulatory authorities, Govt. 
agencies, and IEC. I understand that they are publicly presented. 
13. I have understand that my identity will be kept confidential if my data are publicly 
presented. 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
 
I am aware that if I have any question during this study, I should contact the investigator. By signing 
this consent form I attest that the information given in this document has been clearly explained to 
me and understood by me, I will be given a copy of this consent document 
 
Name and signature / thumb impression of the participant (or legal representative if participant 
incompetent) 
Name ________________ Signature_________________ Date________________ 
Name and Signature of impartial witness (required for illiterate patients): 
Name ________________ Signature_________________ Date________________ 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent 
Name ________________ Signature_________________ Date________________ 
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